Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Ochi, Akinobu ^a   Mori, Katsuhito ^a   Emoto, Masanori ^a   Nakatani, Shinya ^a   Morioka, Tomoaki ^a   Motoyama, Koka ^a   Fukumoto, Shinya ^a   Imanishi, Yasuo ^a   Koyama, Hidenori ^b   Ishimura, Eiji ^a   Inaba, Masaaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TUBULIN; FETUIN A; GLUCOSE; INSULIN; MESSENGER RNA; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD GLUCOSE METER; CONTROLLED STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INSULIN RESISTANCE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT; RECEPTOR UPREGULATION;

ALPHA-2-HS-GLYCOPROTEIN; ANILIDES; ANIMALS; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; MALE; METFORMIN; MICE; MICE, INBRED C57BL; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 84895814181     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088704     Document Type: Article

References (28)

1. Mori K, Emoto M, Inaba M (2011) Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discov 5: 124-146.
2. Mori K, Emoto M, Inaba M (2012) Fetuin-A and the cardiovascular system. Adv Clin Chem 56: 175-195.
3. Stefan N, Haring HU (2013) The role of hepatokines in metabolism. Nat Rev Endcrinol 9: 144-152.
4. Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, et al. (2006) Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 29: 468. (Pubitemid 44106548)
5. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, et al. (2008) Fetuin-A and incident diabetes mellitus in older persons. JAMA 300: 182-188. (Pubitemid 351969302)
6. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, et al. (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57: 2762-2767.
7. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, et al. (1989) Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58: 631-640. (Pubitemid 19210957)
8. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, et al. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116: 3015-3025. (Pubitemid 44684486)
9. Erridge C, Samani NJ (2009) Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler Thromb Vasc Biol 29: 1944-1949.
10. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, et al. (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18: 1279-1285.
11. Stefan N, Haring HU (2013) Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19: 394-395.
12. Derosa G (2010) Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 70: 1945-1961.
13. Mori K, Emoto M, Araki T, Yokoyama H, Lee E, et al. (2008) Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism 57: 1248-1252.
14. Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Loberg EM, et al. (2012) Fetuin-A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endorinol 166: 503-510.
15. Backer JM, Kahn CR, White MF. (1989) Tyrosine phosphorylayion of the insulin receptor during insulin-stimulated internalization in rat hepatoma cells. J Biol Chem 264: 1694-1701. (Pubitemid 19051011)
16. Monden M, Koyama H, Otsuka Y, Morioka T, Mori K, et al. (2013) Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. Diabetes 62: 478-489.
17. Mori K, Giovannone B, Smith RJ (2005) Distinct Grb10 domain requirements for effects on glucose uptake and insulin signaling. Mol Cell Endocrinol 230: 39-50. (Pubitemid 40138969)
18. Jiang Q, Dibra F, Lee MD, Oldenburg R, Uitto J (2010) Overexpression of fetuin-a counteracts ectopic mineralization in a mouse model of pseudoxanthoma elasticum (abcc6(-/-)). J Invest Dermatol 130: 1288-1296.
19. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, et al. (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29: 853-857. (Pubitemid 44115306)
20. Roden M (2006) Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2: 335-348.
21. Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mukhopadhyay S, et al. (2010) NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem J 429: 451-462.
22. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784-1792. (Pubitemid 44033298)
23. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, et al. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112: 91-100. (Pubitemid 38056380)
24. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, et al. (2007) Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 72: 202-207. (Pubitemid 47067382)
25. Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, et al. (2003) Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin- A. Formation of colloidal calciprotein particles. J Biol Chem 278: 13333-13341. (Pubitemid 36800105)
26. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, et al. (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278: 34268-34276. (Pubitemid 37553270)
27. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, et al. (2003) Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111: 737-747. (Pubitemid 36278592)
28. Takata H, Ikeda Y, Suehiro T, Ishibashi A, Inoue M, et al. (2009) High gluose induces transactivation of the a2-HS glycoprotein gene through the ERK1/2 signaling pathway. J Atheroscler Thromb 16: 448-456.